AMPE - Ampio Pharmaceuticals, Inc.
| Previous Close | 2.16 |
| Open | 2.14 |
| Bid | 0.00 x 3100 |
| Ask | 0.00 x 2200 |
| Day's Range | 1.93 - 2.20 |
| 52 Week Range | 0.38 - 4.95 |
| Volume | 905,723 |
| Avg. Volume | 842,119 |
| Market Cap | 176.958M |
| Beta | 1.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.80 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.00 |
- ACCESSWIRE•5 days ago
Free Daily Technical Summary Reports on Amicus Therapeutics and Three Other Biotech Stocks
Stock Research Monitor: AMPE, ANTH, and ARLZ LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want a free Stock Review on FOLD sign up now at www.wallstequities.com/registration . In today's pre-market ...
- PR Newswire•5 days ago
Ampio Updates Scientific presentations and publications on Ampion™
ENGLEWOOD, Colo., May 22, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a poster presentation on the mechanism of action of a component of Ampion™ will be presented at AAST and the most recent study of Ampion treatment of Severe Osteoarthritis of the Knee ( AP-007-B) has been accepted for publication by PSS.
- PR Newswire•13 days ago
Ampio Provides Corporate Update
During Q1, the Company received a total of $3.1 million from investor warrants and stock options being exercised. Discussions with the FDA are ongoing to address FDA questions and provide the company's responses, as the Agency encourages companies to discuss all facets of regulatory filing, including clinical results, labeling, Chemistry, Manufacturing and Controls (CMC), and other aspects of the development process prior to filing their BLA in order to reduce the possibility of receiving a Refusal to File (RTF) notification.
- PR Newswire•25 days ago
The Pivotal Trial Results on Ampion™ (AP-003-C) Was Accepted for Publication in a Peer-Reviewed Medical Journal
ENGLEWOOD, Colo., May 2, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the publication entitled: "Intra-articular injection of the anti-inflammatory compound LMWF-5A (Ampion™) in adults with severe osteoarthritis: a double-blind prospective randomized controlled multicenter safety and efficacy trial" authored by Dr. Brian Cole, MD, Kristin Salottolo MPH and Dr. David Bar-Or, MD was accepted for publication to the peer-reviewed journal "Patient Safety in Surgery".
- Simply Wall St.•26 days ago
Who Really Owns Ampio Pharmaceuticals Inc (NYSEMKT:AMPE)?
In this article, I’m going to take a look at Ampio Pharmaceuticals Inc’s (AMEX:AMPE) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
- Simply Wall St.•last month
How Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) Can Impact Your Portfolio Volatility
If you are a shareholder in Ampio Pharmaceuticals Inc’s (AMEX:AMPE), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
- PR Newswire•last month
Ampio Updates Regulatory, Clinical and NYSE Activities
ENGLEWOOD, Colo., April 12, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announces the Company has begun preliminary discussions with the Food and Drug Administration on details of the Biologics License Application (BLA) submission process for Ampion™, a treatment for severe osteoarthritis-of-the-knee. Second, Nature Biotechnology, a respected journal, with a very high impact factor, has published a commentary on Ampion, our lead drug. Finally, Ampio has received a notification letter from the New York Stock Exchange confirming that Ampio is now in full compliance with their listing requirements.
- PR Newswire•2 months ago
Ampio Updates Regulatory and Clinical Activities
ENGLEWOOD, Colo., April 3, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announces the Company has retained PAREXEL® (www.parexel.com/) to assist in preparing and presenting the Biologics License Application (BLA) for Ampion™ for the treatment of osteoarthritis-of-the-knee (OAK) to the FDA. Mr. Macaluso, Ampio's CEO, noted that "PAREXEL is particularly suited to assist the Company in the preparation and presentation of the BLA to the FDA because their CRO Division helped design and manage the successful pivotal Phase III clinical trial.
- GlobeNewswire•2 months ago
New Research Coverage Highlights Apple Hospitality REIT, J.Jill, Benefitfocus, Ampio Pharmaceuticals, MFA Financial, and Del Frisco's Restaurant Group — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, March 29, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- PR Newswire•2 months ago
Evidence for Delay of Total Knee Replacement (TKR) for Patients with Severe Osteoarthritis of the Knee Receiving Three Intra-articular (IA) Ampion™ Injections
ENGLEWOOD, Colo. , March 26, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced partial results of a follow-up (3.4-3.7 years), double-blind, randomized, controlled trial ...
- PR Newswire•2 months ago
Ampio Pharmaceuticals Provides Corporate Update Following Conference Call
Included below are highlighted disclosures from the corporate update and filed Annual report on Form 10K. Primary endpoint achieved statistical significance when 71% of Ampion-treated patients met the OARSI responder criteria, which exceeded the historically based standard control for a meaningful treatment in severe OAK (p
- PR Newswire•3 months ago
Ampio Hosting Conference Call, Wednesday, March 7, 5:00 pm EST
ENGLEWOOD, Colo. , March 6, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) hosting a conference call Wednesday, March 7th at 5:00 pm EST . Participants are invited to dial in using ...
- Motley Fool•3 months ago
Here's Why Ampio Pharmaceuticals Dropped as Much as 18.8% Today
What goes up must come down.
- Simply Wall St.•3 months ago
Is Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) Still A Cheap Healthcare Stock?
Ampio Pharmaceuticals Inc (AMEX:AMPE), a US$233.14M small-cap, is a healthcare company operating in an industry, which has experienced tailwinds from issues such as higher demand driven by an aging populationRead More...
- Simply Wall St.•4 months ago
Is Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) CEO Salary Justified?
Mike Macaluso is the CEO of Ampio Pharmaceuticals Inc (AMEX:AMPE), which has recently grown to a market capitalization of $220.23M. Understanding how CEOs are incentivised to run and grow theirRead More...
- PR Newswire•4 months ago
Ampio Update of J.P. Morgan Meeting Events and Disease Modification Discussions
ENGLEWOOD, Colo., Jan. 16, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported a heavy schedule of meetings throughout the four-day conference, predominately with significant pharmaceutical companies discussing the successful clinical results of the company's second pivotal phase III trial announced Dec. 14, 2017. The discussions also explored whether Ampion™ could provide not only relief of signs and symptoms of osteoarthritis of the knee (OAK) but also be "a disease-modifying drug" for this condition. David Bar-Or, M.D., Ampio's CSO explained: "OAK, over time, causes progressive loss of cartilage in the knee, which is one of the reasons for limited joint function and chronic pain in this condition (although cartilage has no nerve endings, sub chondral bone does).
- Simply Wall St.•4 months ago
What Does Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) Ownership Structure Look Like?
In this analysis, my focus will be on developing a perspective on Ampio Pharmaceuticals Inc’s (AMEX:AMPE) latest ownership structure, a less discussed, but important factor. The impact of a company’sRead More...
- PR Newswire•5 months ago
Ampio Presentation at J.P. Morgan Healthcare Conference made available to all Shareholders
ENGLEWOOD, Colo. , Jan. 8, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces that the company will be updating potential collaborators and attending shareholders at the J.P. Morgan ...
- Simply Wall St.•5 months ago
Did Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) Recent Earnings Growth Beat The Trend?
Examining how Ampio Pharmaceuticals Inc (AMEX:AMPE) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense checkRead More...
- Motley Fool•5 months ago
Here's Why Ampio Pharmaceuticals Sank as Much as 13.5% Today
An important industry analyst has little hope for the tiny company.
- Motley Fool•5 months ago
3 Biotech Stocks That Soared This Week: Are They Buys?
2017 ended with a bang for these biotech stocks. But can their momentum continue into the new year?
- Motley Fool•5 months ago
Why Ampio Pharmaceuticals Rose as Much as 15% Today
The small-cap biopharma stock has exploded at the end of 2017.
- SmarterAnalyst•5 months ago
Ampio Pharmaceuticals Inc (AMPE) Rallies as Knee Osteoarthritis Drug Findings Cheer
Case in point: Ampio Pharmaceuticals Inc (NYSE:AMPE), whose shares are jumping nearly 50% in Thursday trading session. The biopharmaceutical company reported that its knee osteoarthritis drug Ampion met its primary endpoint in Phase 3 clinical trial. Specifically, 71% of Ampion treated patients met OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee.
- PR Newswire•5 months ago
Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion™ in Severe Osteoarthritis-of-the Knee (OAK)
ENGLEWOOD, Colo., Dec. 14, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported that the Phase 3 clinical trial of Ampion™ met its primary endpoint with 71% of Ampion™ treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee (p
